Poteligeo
Drug
Kyowa Kirin, Inc.
Total Payments
$9.0M
Transactions
6,063
Doctors
3,609
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.7M | 2,910 | 2,010 |
| 2023 | $3.3M | 3,153 | 2,142 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.2M | 319 | 91.5% |
| Space rental or facility fees (teaching hospital only) | $250,841 | 61 | 2.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $241,918 | 67 | 2.7% |
| Food and Beverage | $147,435 | 5,018 | 1.6% |
| Consulting Fee | $88,049 | 32 | 1.0% |
| Travel and Lodging | $25,537 | 149 | 0.3% |
| Education | $9,661 | 417 | 0.1% |
Payments by Type
Research
$8.2M
319 transactions
General
$763,441
5,744 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An open label study to evaluate the safety and efficacy of combination extracorporeal photopheresis (ECP) and mogamulizumab in erythrodermic CTCL | Kyowa Kirin, Inc. | $3.0M | 0 |
| Phase Ib trial of Brentuximab Vedotin in combination with Mogamulizumab in Cutaneous T cell Lymphoma | Kyowa Kirin, Inc. | $1.9M | 0 |
| Pilot Study of Concurrent Phototherapy and Mogamulizumab in Early Stage Mycosis Fungoides | Kyowa Kirin, Inc. | $987,618 | 0 |
| Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) | Kyowa Kirin, Inc. | $872,201 | 0 |
| A Prospective, US-based Study Assesing Mogamulizumab-Associated Rash in Patients Diagnosed with Mycosis Fungoides or Sezary Syndrome and Treated with Standard of Care Mogamulizumab | Kyowa Kirin, Inc. | $371,835 | 0 |
| Phase II study of mogamulizumab with EPOCH in patients with aggressive T cell lymphoma | Kyowa Kirin, Inc. | $244,642 | 0 |
| Prospective Research Based Observational Study of Poteligeo Experience in the Real World in Adult Patients With Mycosis Fungoides and Sezary Syndrome | Kyowa Kirin Services Ltd | $206,790 | 0 |
| Phase 2 Study for Prevention of Adult T-cell Leukemia/Lymphoma with Mogamulizumab in High Risk Carriers of HTLV-1 | Kyowa Kirin, Inc. | $185,097 | 0 |
| Characterization TumorHost Interaction that Influences Anti-Tumor Immune Response in Black Patients Vs. White Patients with Mycosis Fungoides and Sezary Syndrome | Kyowa Kirin, Inc. | $150,000 | 0 |
| Post-authorisation safety study of allogeneic haematopoietic cell transplantation in patients treated with mogamulizumab | Kyowa Kirin Services Ltd | $122,705 | 0 |
| Real-World Outcomes and Tolerability of Mogamulizumab Monotherapy and Multimodality Therapy for Cutaneous T-Cell Lymphoma | Kyowa Kirin, Inc. | $88,140 | 0 |
| Development of new lymph node response criteria by using novel radiological quantitative techniques. | Kyowa Kirin, Inc. | $53,772 | 0 |
| A multicenter open-label phase II study of tazemetostat in combination with mogamulizumab in relapsed/refractory advanced stage (IIb-IV) mycosis fungoides/Sezary syndrome and PTCL | Kyowa Kirin, Inc. | $45,967 | 0 |
Top Doctors Receiving Payments for Poteligeo
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Alison Tran | — | New York, NY | $8.5M | 400 |
| , M.D., PH.D | Dermatology | Pittsburgh, PA | $115,536 | 153 |
| , MD | Dermatology | Birmingham, AL | $43,672 | 28 |
| , M.D | Dermatology | Dublin, OH | $22,328 | 28 |
| , MD | Dermatopathology | Evanston, IL | $21,300 | 7 |
| , M.D | Dermatology | Portland, OR | $21,289 | 20 |
| , M.D., PH.D | Medical Oncology | New York, NY | $17,292 | 19 |
| , MD | Internal Medicine | Baltimore, MD | $14,195 | 26 |
| , MD, PHD | Dermatology | Duarte, CA | $13,328 | 20 |
| , MD | Dermatopathology | Charlottesville, VA | $11,747 | 15 |
| , MD | Dermatology | Phoenix, AZ | $11,485 | 7 |
| , M.D | Specialist | Chapel Hill, NC | $7,310 | 6 |
| , MD | Dermatology | New York, NY | $6,850 | 18 |
| , NP | Nurse Practitioner | Burbank, CA | $6,484 | 13 |
| , M.D | Hematology & Oncology | Miami, FL | $6,064 | 6 |
| , MPAS PA-C | Physician Assistant | Boulder, CO | $4,285 | 23 |
| , M.D.,PH.D | Specialist | East Setauket, NY | $3,550 | 1 |
| , M.D | Dermatology | New Orleans, LA | $3,424 | 3 |
| , M.D | Medical Oncology | Naples, FL | $2,879 | 3 |
| , M.D., PHD | Dermatology | Santa Monica, CA | $2,878 | 5 |
| , MD | Dermatology | Miami, FL | $2,753 | 3 |
| , MD | Medical Oncology | New Haven, CT | $2,670 | 7 |
| , MD | Dermatology | Moreland Hills, OH | $2,576 | 2 |
| , M.D | Radiation Oncology | Stanford, CA | $2,522 | 2 |
| , M.D | Hematology & Oncology | Phoenix, AZ | $2,500 | 4 |
Ad
Manufacturing Companies
- Kyowa Kirin, Inc. $8.7M
- Kyowa Kirin Services Ltd $329,495
Product Information
- Type Drug
- Total Payments $9.0M
- Total Doctors 3,609
- Transactions 6,063
About Poteligeo
Poteligeo is a drug associated with $9.0M in payments to 3,609 healthcare providers, recorded across 6,063 transactions in the CMS Open Payments database. The primary manufacturer is Kyowa Kirin, Inc..
Payment data is available from 2023 to 2024. In 2024, $5.7M was paid across 2,910 transactions to 2,010 doctors.
The most common payment nature for Poteligeo is "Unspecified" ($8.2M, 91.5% of total).
Poteligeo is associated with 13 research studies, including "An open label study to evaluate the safety and efficacy of combination extracorporeal photopheresis (ECP) and mogamulizumab in erythrodermic CTCL" ($3.0M).